Please login to the form below

Not currently logged in
Email:
Password:

chronic spontaneous urticaria

This page shows the latest chronic spontaneous urticaria news and features for those working in and with pharma, biotech and healthcare.

Novartis funds chronic urticaria app and patient community

Novartis funds chronic urticaria app and patient community

Novartis funds chronic urticaria app and patient community. My Hives has been developed, and will be run, by Exco InTouch. ... Novartis is funding a new mobile app and website that aims to create an online support community for patients with chronic

Latest news

  • 90TEN and ICG win market research award at Communiqué 2015 90TEN and ICG win market research award at Communiqué 2015

    Their'Wheals of Despair'campaign, created for Novartis UK, focused on chronic spontaneous urticaria (CSU) - a condition that was until recently a mystery to many doctors and almost completely unknown to

  • NICE set to back Novartis' Xolair for skin condition CSU NICE set to back Novartis' Xolair for skin condition CSU

    NICE set to back Novartis' Xolair for skin condition CSU. Issues final draft guidance on the treatment's use as an add-on for chronic spontaneous urticaria. ... NICE is poised to recommend Novartis' Xolair as an add-on treatment option for severe chronic

  • Novartis' dermatology plans advance with Xolair approval Novartis' dermatology plans advance with Xolair approval

    Novartis' dermatology plans advance with Xolair approval. Green light for use in chronic spontaneous urticaria. ... Novartis' asthma drug Xolair has been approved in Europe for a new indication, the treatment of a severe form of hives known as chronic

  • CHMP backs Xolair for severe hives CHMP backs Xolair for severe hives

    The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Xolair (omalizumab) for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU). ... Chronic urticaria affects around 1 per cent of the

  • Novartis' omalizumab effective in chronic skin disease Novartis' omalizumab effective in chronic skin disease

    The active ingredient in Xolair (omalizumab) has been found to be effective as a treatment for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU) in the ... Novartis filed for approval of omalizumab a few weeks ago as a

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics